Mats-Olof Wallin

Director of Finance/CFO at OxThera AB

73 year

Health Technology

Consumer Services

Profile

Mats-Olof Wallin is currently the Chief Financial Officer & Deputy CEO at OxThera AB since 2020.
Prior to this, he worked as the CFO & Director-Investor Relations at Biotage AB from 2003 to 2012, the Chief Financial Officer at Karo Healthcare AB from 2018 to 2019, and the Chief Financial Officer & Senior Vice President at Swedish Orphan Biovitrum AB from 2013 to 2018.
He completed his undergraduate degree from the University of Uppsala.

Mats-Olof Wallin active positions

Companies	Position	Start
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Director of Finance/CFO	2019-12-31

All active positions of Mats-Olof Wallin

Former positions of Mats-Olof Wallin

Companies	Position	End
KARO PHARMA AB (PUBL)	Director of Finance/CFO	2019-09-30
SWEDISH ORPHAN BIOVITRUM AB	Director of Finance/CFO	2018-07-19
BIOTAGE AB	Director of Finance/CFO	2011-12-31

See the detail of Mats-Olof Wallin's experience

Training of Mats-Olof Wallin

University of Uppsala

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Mats-Olof Wallin's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
BIOTAGE AB	Health Technology
SWEDISH ORPHAN BIOVITRUM AB	Health Technology
KARO PHARMA AB (PUBL)	Health Technology

Private companies	1
OxThera AB OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden.	Health Technology